학술논문
Anti-TNFα Treatment Impairs Long-Term Immune Responses to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases
Document Type
article
Author
Keren Masha Rabinowitz; Michal Navon; Hadar Edelman-Klapper; Eran Zittan; Ariella Bar-Gil Shitrit; Idan Goren; Irit Avni-Biron; Jacob E. Ollech; Lev Lichtenstein; Hagar Banai-Eran; Henit Yanai; Yifat Snir; Maor H. Pauker; Adi Friedenberg; Adva Levy-Barda; Arie Segal; Yelena Broitman; Eran Maoz; Baruch Ovadia; Maya Aharoni Golan; Eyal Shachar; Shomron Ben-Horin; Nitsan Maharshak; Michal Mor; Haim Ben Zvi; Rami Eliakim; Revital Barkan; Tali Sharar-Fischler; Sophy Goren; Noy Krugliak; Edward Pichinuk; Michael Mor; Michal Werbner; Joel Alter; Hanan Abu-Taha; Kawsar Kaboub; Moshe Dessau; Meital Gal-Tanamy; Dani Cohen; Natalia T. Freund; Iris Dotan; on behalf of the Responses to COVID-19 Vaccine Israeli IBD Group
Source
Vaccines, Vol 10, Iss 8, p 1186 (2022)
Subject
Language
English
ISSN
10081186
2076-393X
2076-393X
Abstract
Patients with inflammatory bowel disease (IBD) treated with anti-tumor-necrosis factor-alpha (TNFα) exhibited lower serologic responses one-month following the second dose of the COVID-19 BNT162b2 vaccine compared to those not treated with anti-TNFα (non-anti-TNFα) or to healthy controls (HCs). We comprehensively analyzed long-term humoral responses, including anti-spike (S) antibodies, serum inhibition, neutralization, cross-reactivity and circulating B cell six months post BNT162b2, in patients with IBD stratified by therapy compared to HCs. Subjects enrolled in a prospective, controlled, multi-center Israeli study received two BNT162b2 doses. Anti-S levels, functional activity, specific B cells, antigen cross-reactivity, anti-nucleocapsid levels, adverse events and IBD disease score were detected longitudinally. In total, 240 subjects, 151 with IBD (94 not treated with anti-TNFα and 57 treated with anti-TNFα) and 89 HCs participated. Six months after vaccination, patients with IBD treated with anti-TNFα had significantly impaired BNT162b2 responses, specifically, more seronegativity, decreased specific circulating B cells and cross-reactivity compared to patients untreated with anti-TNFα. Importantly, all seronegative subjects were patients with IBD; of those, >90% were treated with anti-TNFα. Finally, IBD activity was unaffected by BNT162b2. Altogether these data support the earlier booster dose administration in these patients.